

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P30653Application No.  
10/598,275INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)Applicant  
Ryozo NAGAI et al.Filing Date  
February 24, 2005Group 1611  
~~Unknown~~

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4 9 1 7 8 2 9	04/17/90	YAMATSU et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	56	- 1 4 0 9 4 9	11/04/81	JAPAN				
	63	- 3 2 0 5 8	06/28/82	JAPAN				
	7	- 1 1 2 9 3 0	05/02/95	JAPAN				
	61	- 2 1 0 0 5 0	09/18/86	JAPAN				
		0 1 9 4 6 9 3	09/19/86	E.P.O				
	59	- 1 0 1 4 4 8	06/12/84	JAPAN				
		0 1 1 0 3 9 7	06/13/84	E.P.O				
	10	- 3 1 6 6 1 7	12/02/98	JAPAN				
	4	- 1 7 8 3 4 8	06/25/92	JAPAN				
	11	- 3 1 8 4 5 0	11/24/99	JAPAN				
	2003	/ 0 8 9 0 0 5	10/30/05	W.I.P.O				
	2005	/ 0 1 0 1 8 5	02/03/05	W.I.P.O				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	J. GEORGE et al., "Inhibition of Intimal Thickening in the Injury Model by a Nontoxic Ras Inhibitor", Arterioscler Thromb Vasc. Biol. Feb. 2004, Vol. 24, No. 2, pp. 363-368.
2	Y. MUTO et al., "Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma", N. Engl. J. Med., June 13, 1996, Vol. 334, No. 24, pp. 1561-1567.
3	N. WATANBE et al., "BTEB2, A Krüppel-Like Transcription Factor, Regulates Expression of the SMemb/Nonmuscle Myosin Heavy Chain B (SMemb/NMHC-B) Gene", Circulation Research, 85, pp.182-191, 1999.
4	T. SHINDO et al., "Krüppel-Like Zinc-Finger Transcription Factor KLF5/BTEB2 is a Target for Angiotensin II Signaling and an Essential Regulator of Cardiovascular Remodeling", Nature Medicine, Vol. 8, No. 8, pp.856-863, July 8, 2002.
5	J. DAVIS et al., "Cartenoids and Related Compounds. Part XV. The Structure and Synthesis of Phytoene, Phytofluene, $\zeta$ -Carotene, and Neurosporene", J. Chem. Soc., 1966, pp.2154-2165.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

U.S. Department of Commerce  
Patent and Trademark Office

Application No.  
10/598,275

Applicant  
Ryozo NAGAI et al.

Group  
Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
02/10/2008						

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	6	English language Abstract of JP 56-140949.
	7	English language Abstract of JP 7-112930.
	8	English language Abstract of JP 61-210050.
	9	English language Abstract of JP 10-316617.
	10	English language Abstract of JP 4-178348.
	11	English language Abstract of JP 11-318450.
	12	U.S. Patent Application 10/511,274 (NAGAI et al.), entitled, "Medicament for Therapeutic Treatment of Vascular Disease"
	13	U.S. Patent Application 10/565,997 (NAGAI et al.), entitled, "RNA Capable of Suppressing Expression of KLF5 Gene"
	14	U.S. Patent Application 11/366,454 (NAGAI et al.), entitled, "Medicament Having Neovascularization Promoting Action".

7/CR/ 

02/10/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{P30653 00161177.DOC} ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

02/10/2008